A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

about

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Item

http://www.wikidata.org/entity/Q40522671

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

@en

type

Item

label

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

@en

prefLabel

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

@en

P1476

A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

@en

P2093

Benjamin D Grant

http://www.w3.org/2001/XMLSchema#string

Chelsey A Smith

http://www.w3.org/2001/XMLSchema#string

Michael E Scheurer

http://www.w3.org/2001/XMLSchema#string

Philip E Castle

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Installing and implementing a computer-based patient record system in sub-Saharan Africa: the Mosoriot Medical Record System.

Multiplexed serologic assay for nine anogenital human papillomavirus types.

Maturation of papillomavirus capsids.

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine.

P304

5656-5663

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2016.09.021

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rebecca R. Richards-Kortum

P577

2016-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27667331

http://www.w3.org/2001/XMLSchema#string

P932

5075515

http://www.w3.org/2001/XMLSchema#string